Concurrent with the transaction, the sellers, now operating as Opus Bio, Inc., have been granted certain rights to deploy lentiviral technology in some therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s integrated tools support research at every level, from basic research to translational research to clinical application. Their technologies cover techniques of sample preparation, cell isolation, flow sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. The company’s more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. Trusted around the world, the Miltenyi Biotec brand continues to set new standards in the industry. Miltenyi Biotec has more than 1,400 employees in 25 countries.
Tel. +44 (0)1480 471045